Skip to main content

Table 3 Main clinical outcomes of hospitalization

From: Epidemiology and outcomes of multidrug-resistant bacterial infection in non-cystic fibrosis bronchiectasis

 

Control group

MDR group

p-value

MDR-AB

ESBL-E coli

ESBL-KP

MDR-Pseudomonus

MRSA

p-value

 

n=1108

n=554

 

n=214

n=47

n=99

n=82

n=102

 

Length of ward (days)

12.6 ± 10.5

26.4 ± 22.3

<0.001

27.3 ± 16.8

29.9 ± 20.5

27.3 ± 17.5

28.6 ± 42.2

20.3 ± 12.8

0.043

Length of ICU (days)

9.8 ± 9.2

18.9 ± 14.2

<0.001

19.3 ± 12.5

17.2 ± 16.9

20.0 ± 14.6

22.4 ± 18.5

13.7 ± 12.6

0.068

Respiratory failure

137 (12.4%)

229 (41.3%)

<0.001

97 (45.3%)

11 (23.4%)

41 (41.4%)

36 (43.9%)

41 (40.2%)

0.096

 Invasive MV

77 (6.9%)

150 (27.1%)

<0.001

69 (32.2%)

7 (14.9%)

28 (28.3%)

26 (31.7%)

19 (18.6%)

0.027

 Non-invasive MV

89 (8.0%)

125 (22.6%)

<0.001

42 (19.6%)

7 (14.9%)

22 (22.2%)

21 (25.6%)

31 (30.4%)

0.156

Duration of ventilator (days)

7.8 ± 7.4

17.9 ± 13.7

<0.001

18.2 ± 12.8

17.1 ± 13.6

18.5 ± 13.9

21.6 ± 18.2

11.7 ± 9.1

0.033

Shock

67 (6.1%)

169 (30.5%)

<0.001

68 (31.8%)

9 (19.2%)

40 (40.4%)

23 (28.1%)

25 (24.5%)

0.048

Inhospital mortality

83 (7.6%)

148 (26.7%)

<0.001

67 (31.3%)

10 (21.3%)

27 (27.3%)

15 (18.3%)

27 (26.5%)

0.201

Convert to non-MDR

(%)

233 (42.1%)

 

88 (41.1%)

24 (51.1%)

39 (39.4%)

31 (37.8%)

45 (44.1%)

0.609

Time to non-MDR (days)

(%)

27.2 ± 64.8

 

15.1 ± 29.1

37.5 ± 52.6

28.9 ± 87.1

32.8 ± 71.9

47.3 ± 94.8

0.004

3 year Respiratory failure

150 (13.5%)

186 (33.6%)

<0.001

79 (36.9%)

11 (23.4%)

35 (35.4%)

35 (42.7%)

23 (22.6%)

<0.001

 Invasive MV

101 (9.1%)

149 (26.9%)

<0.001

66 (30.8%)

7 (14.9%)

29 (29.3%)

32 (39.0%)

14 (13.7%)

<0.001

 Non-invasive MV

87 (7.9%)

84 (15.2%)

<0.001

30 (14.0%)

6 (12.8%)

14 (14.1%)

13 (15.9%)

18 (17.7%)

0.001

3 year mortality

460 (41.5%)

406 (73.3%)

<0.001

166 (77.6%)

32 (68.1%)

80 (80.8%)

48 (58.5%)

71 (69.6%)

<0.001

  1. Note AB, Acinetobacter baumannii; ESBL, extended-spectrum-beta-lactamases; KP, Klebsiella pneumoniae; MDR: multidrug- resistant; MRSA, methicillin-resistant Staphylococcus aureus; MV, mechanical ventilator